Document Detail


Detection of prostate cancer and predicting progression: current and future diagnostic markers.
MedLine Citation:
PMID:  15217924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Carcinoma of the prostate is the second leading cause of male cancer-related death in the United States. Better indicators of prostate cancer presence and progression are needed to avoid unnecessary treatment, predict disease course, and develop more effective therapy. Numerous molecular markers have been described in human serum, urine, seminal fluid, and histological specimens that exhibit varying capacities to detect prostate cancer and predict disease course. However, to date, few of these markers have been adequately validated for clinical use. The purpose of this review is to examine the current status of these markers in prostate cancer and to assess the diagnostic potential for future markers from identified genes and molecules that display loss, mutation, or alteration in expression between tumor and normal prostate tissues. In this review we cite 91 molecular markers that display some level of correlation with prostate cancer presence, disease progression, cancer recurrence, prediction of response to therapy, and/or disease-free survival. We suggest criteria to consider when selecting a marker for further development as a clinical tool and discuss five examples of markers (chromogranin A, glutathione S-transferase pi 1, prostate stem cell antigen, prostate-specific membrane antigen, and telomerase reverse transcriptase) that fulfill some of these criteria. Finally, we discuss how to conduct evaluations of candidate prostate cancer markers and some of the issues involved in the validation process.
Authors:
James V Tricoli; Mason Schoenfeldt; Barbara A Conley
Related Documents :
18774484 - Does diabetes mellitus as a comorbid condition affect the health-related quality of lif...
20088874 - The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
11549474 - Dna-based detection of prostate cancer in urine after prostatic massage.
20808724 - Role of chemokines and chemokine receptors in prostate cancer development and progression.
7509744 - Photodynamic therapy in gastroenterology--current status and future prospects.
23839094 - Intercellular communication by exosome-derived micrornas in cancer.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  10     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-25     Completed Date:  2005-01-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3943-53     Citation Subset:  IM    
Affiliation:
Diagnostics Research Branch, Cancer Diagnosis Program, National Cancer Institute, Rockville, Maryland, USA. tricolij@mail.nci.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, Surface / biosynthesis
Chromogranin A
Chromogranins / biosynthesis
DNA-Binding Proteins
Disease Progression
Glutamate Carboxypeptidase II / biosynthesis
Glutathione Transferase / biosynthesis
Humans
Male
Membrane Glycoproteins / biosynthesis
Neoplasm Proteins / biosynthesis
Prostatic Neoplasms / diagnosis*,  pathology*
Telomerase / biosynthesis
Tumor Markers, Biological*
Chemical
Reg. No./Substance:
0/Antigens, Surface; 0/Chromogranin A; 0/Chromogranins; 0/DNA-Binding Proteins; 0/Membrane Glycoproteins; 0/Neoplasm Proteins; 0/PSCA protein, human; 0/Tumor Markers, Biological; EC 2.5.1.18/Glutathione Transferase; EC 2.7.7.49/Telomerase; EC 3.4.17.21/Glutamate Carboxypeptidase II; EC 3.4.17.21/glutamate carboxypeptidase II, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mesothelin: a new target for immunotherapy.
Next Document:  A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: int...